Returns–Not enough quarters yet
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| RLMDRelmada Therapeutics Inc | $50.9M | 17.4% | −13.3% |
| CCCCC4 Therapeutics Inc | $33.6M | 11.5% | +220.0% |
| COGTCogent Biosciences Inc | $33.5M | 11.5% | +9.8% |
| KODKodiak Sciences Inc | $19.5M | 6.7% | +31.6% |
| RLAYRelay Therapeutics Inc | $18.1M | 6.2% | +44.2% |
| ZNTLZentalis Pharmaceuticals Inc | $17.9M | 6.1% | +1.9% |
| EWTXEdgewise Therapeutics Inc | $11.8M | 4.0% | −17.1% |
| MAZEMaze Therapeutics Inc | $10.0M | 3.4% | +30.1% |
| IVAInventiva Sa | $9.2M | 3.2% | +355.1% |
| ANLAdlai Nortye Ltd | $8.8M | 3.0% | −39.5% |
| ELVNEnliven Therapeutics Inc | $8.1M | 2.8% | New |
| PALIPalisade Bio Inc | $6.3M | 2.1% | |
| IKTInhibikase Therapeutics Inc | $6.1M | 2.1% | −14.3% |
| ADAGAdagene Inc | $5.2M | 1.8% | New |
| Forte Biosciences IncCUSIP 34962G208 | $4.8M | 1.6% | New |
| Inflarx NvCUSIP N44821101 | $4.5M | 1.5% | New |
| ASMBAssembly Biosciences Inc | $4.4M | 1.5% | New |
| PMNPromis Neurosciences Inc | $4.3M | 1.5% | |
| CTNMContineum Therapeutics Inc | $4.3M | 1.5% | New |
| CMPSCompass Pathways PLC | $4.2M | 1.5% | New |
| DFTXDefinium Therapeutics Inc | $4.0M | 1.4% | New |
| Sol-gel Technologies LtdCUSIP M8694L137 | $3.9M | 1.3% | +67.7% |
| BIOABioage Labs Inc | $3.8M | 1.3% | New |
| SCYXScynexis Inc | $3.1M | 1.1% | New |
| Proqr Thrapeutics N VCUSIP N71542109 | $2.8M | 1.0% | New |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| ZNTLZentalis Pharmaceuticals Inc | March 31, 2026 | +107.3% | $17.9M |
| RLAYRelay Therapeutics Inc | March 31, 2026 | +88.0% | $18.1M |
| CCCCC4 Therapeutics Inc | March 31, 2026 | +77.6% | $33.6M |
| ANLAdlai Nortye Ltd | March 31, 2026 | +66.2% | $8.8M |
| EWTXEdgewise Therapeutics Inc | December 31, 2025 | +63.7% | $11.8M |
| RLMDRelmada Therapeutics Inc | December 31, 2025 | +43.3% | $50.9M |
| KODKodiak Sciences Inc | December 31, 2025 | +39.3% | $19.5M |
| COGTCogent Biosciences Inc | December 31, 2025 | +9.0% | $33.5M |
| PMNPromis Neurosciences Inc | March 31, 2026 | +3.6% | $4.3M |
| IKTInhibikase Therapeutics Inc | December 31, 2025 | −1.0% | $6.1M |
Sold off last quarter
- Kalvista Pharmaceuticals IncCUSIP 483497103 was $19.8M
- ABVXAbivax Sa was $14.5M
- NKTRNektar Therapeutics was $9.0M
- Scynexis IncCUSIP 811292200 was $7.0M
- EPRXEupraxia Pharmaceuticals Inc was $4.9M
- Gh Research PLCCUSIP G3855L106 was $4.6M
- ALXOAlx Oncology Hldgs Inc was $2.9M
- CNTXContext Therapeutics Inc was $2.9M
- TRAWTraws Pharma Inc was $936K
- TXMDTherapeuticsmd Inc was $849K
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +16.4% | +14.8% |
| March 31, 2026 | +3.7% | −4.6% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Squadron Capital Management LLC Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=2050709&type=13F-HR&dateb=&owner=include&count=40CIK 2050709
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/2050709/000205070926000027/Filed August 14, 2026 · accession 0002050709-26-000027